Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653623 | 0.73 | KMT2A (0.42) | SMN1; SMN2GCK | |
| SCHEMBL1654922 | 0.72 | CBLB (0.37) | SMN1; SMN2GCK | |
| SCHEMBL1653468 | 0.71 | ABCB1 (0.37) | SMN1; SMN2 | |
| SCHEMBL1654332 | 0.71 | HPGD (0.31) | — | |
| SCHEMBL1653371 | 0.69 | PORCN (0.31) | — | |
| SCHEMBL1655577 | 0.68 | METAP1 (0.35) | — | |
| SCHEMBL1653103 | 0.68 | HSP90AA1 (0.40) | — | |
| SCHEMBL1653949 | 0.67 | METAP1 (0.37) | — | |
| SCHEMBL12783283 | 0.67 | METAP1 (0.37) | — | |
| SCHEMBL1653108 | 0.67 | CYP2A6 (0.42) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | DHODH 731/4885SMN1; SMN2 4353/4885GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.